Siemens Healthineers and Mayo Clinic Expand Partnership to Advance Patient Care

Siemens Healthineers and Mayo Clinic are set to broaden their strategic partnership, focusing on improving patient care in areas including neurodegenerative diseases, prostate cancer, and metastatic liver tumors. This collaboration is designed to enhance access to advanced imaging and interventional technologies, offering new possibilities for the diagnosis and management of these conditions.

This joint effort will initially focus on several key areas:

1. Neurodegenerative Diseases: The partnership aims to advance AI-powered MRI protocols to enhance diagnostic precision and patient monitoring capabilities.
2. Surgical Care Innovations: By incorporating digital twin technologies, Siemens Healthineers and Mayo Clinic seek to transform patient experiences during surgery, improving both operational efficiency and patient outcomes.
3. Prostate Cancer: Together, they will explore AI applications in reducing the need for biopsies, as well as integrating advanced, minimally invasive imaging into both diagnostic and therapeutic procedures.
4. Minimally Invasive Image-Guided Interventions: Efforts will focus on the clinical translation of imaging technologies for accurate detection and treatment of liver metastases.
5. Ultra-High-Field MRI Innovation: The collaboration will work on the clinical adoption of ultra-high-field MRI protocols, which offer enhanced resolution and contrast for complex neurological conditions.
6. Whole Body PET/CT and PET/MR Advancements: Aimed at incorporating theranostics, this initiative will focus on simultaneous anatomical and metabolic imaging to refine diagnostic and therapeutic planning for several cancers.

Eric Williamson, MD, chair of diagnostic radiology at Mayo Clinic, stated, "Our goal is to make care more precise, less invasive, and more responsive to each patient’s needs. By expanding our collaboration, we can bring advanced imaging, artificial intelligence, and innovative treatment approaches directly into everyday clinical care, potentially helping patients receive earlier diagnoses, more personalized treatment plans, and better outcomes."

Similarly, John Kowal, president and head of the Americas at Siemens Healthineers, emphasized the importance of the collaboration, adding, "Improving the diagnosis and treatment of neurodegenerative disease and cancer is core to our purpose as a company. Our collaboration with Mayo Clinic creates significant opportunities to help extend the quantity and quality of patients’ lives."

The enhanced collaboration between Siemens Healthineers and Mayo Clinic signifies a commitment to leveraging technology and innovation in healthcare to improve patient outcomes across critical disease areas.